Literature DB >> 26217925

Six-Year Clinical Outcomes After Catheter Ablation of Atrial Fibrillation in Patients With Impaired Left Ventricular Function.

Andreas Rillig1, Hisaki Makimoto1, Jascha Wegner1, Tina Lin1, Christian Heeger1, Christine Lemes1, Thomas Fink1, Andreas Metzner1, Erik Wissner1, Shibu Mathew1, Peter Wohlmuth2, Karl-Heinz Kuck1, Roland Richard Tilz1, Feifan Ouyang1.   

Abstract

INTRODUCTION: Long-term data after pulmonary vein isolation (PVI) in patients with impaired systolic left ventricular ejection fraction (LVEF) are sparse. This study assessed the outcomes in patients with atrial fibrillation (AF) and reduced LVEF treated with PVI after a median follow-up period of 6 years. METHODS AND
RESULTS: Eighty-one patients with an LVEF≤45% were evaluated; however, 1 patient was lost to follow-up. In the remaining 80 patients (male: n = 68 (85%), median age 61.6 (54.8-67.5) years) with paroxysmal (n = 16, 20%), persistent (n = 37, 46.2%), and longstanding-persistent AF (LS-AF), catheter ablation of AF using radiofrequency and 3D mapping was performed. Follow-up included Holter monitoring or pacemaker/ICD interrogation to assess for arrhythmia recurrence and echocardiography to assess LVEF. Median follow-up was 72 (67-75) months. Death occurred in 21 patients. Single-procedure success rate was 35.1% and multiple-procedure success rate was 56.8% in the overall group. Baseline median LVEF (35% [28.5-40%]) significantly increased at 6-year follow-up (56.5% [40.0-60.0%], P < 0.01). In patients with single- or multiple-procedure ablation success, there was a higher improvement of LVEF (single procedure: 25% [15.0-35] vs. 10.0% [-1.0-20.0], P < 0.01; multiple procedures: 20.0% [15-34] vs. 5.0% [5.00-15.0]; P < 0.01). The single (43.8% vs. 40%, P = 0.96) and multiple procedure success rates (62.5% vs. 60%, P = 0.47) were comparable between patients with PAF and persistent AF and lowest in patients with LS-AF (single procedure success: 23.1%, multiple-procedure success: 47.8%).
CONCLUSION: Single-procedure success rates after PVI during 6 years of follow-up were low. In patients with single- or multiple-procedure ablation success, a higher improvement of LVEF was observed.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; catheter ablation; heart failure; impaired systolic ejection fraction; long-term follow-up; pulmonary vein isolation

Year:  2015        PMID: 26217925     DOI: 10.1111/jce.12765

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

Review 1.  [Pulmonary vein isolation for atrial fibrillation : Findings from long-term follow-up].

Authors:  C-H Heeger; K-H Kuck; F Ouyang
Journal:  Herz       Date:  2017-06       Impact factor: 1.443

2.  Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure.

Authors:  Guojun Zhao; Leiming Wu; Yuzhou Liu; Lu Gao; Yang Chen; Rui Yao; Yanzhou Zhang
Journal:  Biomed Rep       Date:  2017-01-17

Review 3.  Who Needs Catheter Ablation And Which Approach?

Authors:  Duygu Kocyigit; Ugur Canpolat; Kudret Aytemir
Journal:  J Atr Fibrillation       Date:  2015-12-31

Review 4.  Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction.

Authors:  Jackson J Liang; David J Callans
Journal:  Card Fail Rev       Date:  2018-05

5.  Catheter Ablation for Persistent Atrial Fibrillation in Class IV Systolic Heart Failure: A Single-Center Case Series.

Authors:  Aaron Hesselson; Heather Hesselson
Journal:  J Atr Fibrillation       Date:  2021-04-30

6.  Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure.

Authors:  Andreas Rillig; Christina Magnussen; Ann-Kathrin Ozga; Anna Suling; Axel Brandes; Günter Breithardt; A John Camm; Harry J G M Crijns; Lars Eckardt; Arif Elvan; Andreas Goette; Michele Gulizia; Laurent Haegeli; Hein Heidbuchel; Karl-Heinz Kuck; Andre Ng; Lukasz Szumowski; Isabelle van Gelder; Karl Wegscheider; Paulus Kirchhof
Journal:  Circulation       Date:  2021-07-30       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.